Thursday Jul 24
Adocia Reports Operational And Financial Results For The First Half Of 2014
Major clinical results reported on two formulations based on insulin Sound financial position with approximately EUR 16 million in cash at LYON, France-- --July 24, 2014-- Regulatory News: Adocia , a biotechnology company specialized in the development of 'best-in-class' medicines from already approved therapeutic proteins, announces today its ... (more)
Thursday Jul 24
The Washington Post
Eli Lilly Beats Quarterly Estimates on Diabetes Drug Sales
Eli Lilly & Co., the drugmaker experiencing a wave of sales losses as patents expire, reported second quarter profit that beat analysts' estimates with better than expected sales of its diabetes drug Humalog.
Adocia Announces Approval To Start A Phase IIa Clinical Study Of...
HinsBet's objective is to improve human insulin performance in a cost-effective way Phase IIa study will compare HinsBet to a fast-acting insulin analog and a regular human insulin in type 1 diabetic patients First Patient In planned for the first week of August Lyon, France, July 9th, 2014 - Adocia announced today that BfArM , the German ... (more)
The Motley Fool
MannKind Stock: Afrezza Approved at Last, But Will Sales Disappoint?
Approval is a major event for MannKind, but the company still needs a commercial partner and the approved label for Afrezza doesn't do the product/company any particular favors.
UPDATE 3-U.S. FDA approves MannKind's inhaled insulin, Afrezza
The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.